CDK4/6 inhibitors: advances in breast cancer management
Join Dr Nadia Harbeck and Professor Alessandra Gennari in this podcast series on risk assessment and CDK4/6 inhibitors for the treatment of early breast cancer. This podcast is intended for registered Healthcare Professionals only. Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
Episodes
Wednesday Nov 15, 2023
Wednesday Nov 15, 2023
How might the early breast cancer treatment landscape change over the next 2 years? Dr Nadia Harbeck and Professor Michael Gnant review findings presented at ESMO 2023 and discuss approaches to optimal treatment selection in a rapidly evolving treatment landscape.
Wednesday Nov 15, 2023
Wednesday Nov 15, 2023
Recurrence risk is an important factor that must be considered in the treatment of early breast cancer. Dr Nadia Harbeck and Professor Michael Gnant discuss how recurrence risk and other factors can inform treatment selection.
Wednesday Nov 15, 2023
Wednesday Nov 15, 2023
Dr Nadia Harbeck and Professor Michael Gnant review the latest clinical trial evidence for CDK4/6 inhibitors in the early breast cancer setting and discuss what the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approval of abemaciclib means for clinicians and people with early breast cancer.
Thursday Sep 22, 2022
Thursday Sep 22, 2022
Dr Nadia Harbeck and Professor Alessandra Gennari review the completed clinical trials for CDK4/6 inhibitors in early breast cancer, namely PALLAS and PENELOPE-B for palbociclib and monarchE for abemaciclib. The divergent results for palbociclib and abemaciclib were unexpected, particularly as both proved effective in the metastatic setting and are now standard therapy for this indication. Dr Harbeck and Professor Gennari share their views on the possible reasons for the different outcomes with palbociclib and abemaciclib in early breast cancer.
Thursday Sep 22, 2022
Thursday Sep 22, 2022
Dr Nadia Harbeck and Professor Alessandra Gennari delve deeper into the RxPonder trial to explore the design and primary outcomes of the trial. Dr Harbeck and Professor Gennari discuss how RxPonder validated the use of the 21-gene expression assay as a tool to identify patients who could be spared chemotherapy.
Thursday Sep 22, 2022
Thursday Sep 22, 2022
Dr Nadia Harbeck and Professor Alessandra Gennari discuss ground-breaking trials, including the TailorX and RxPonder trials, that validated the use of gene expression assays to inform therapy decisions for patients with early breast cancer. Dr Harbeck also describes the ADAPT series, which combines gene expression assays with endocrine response to individualise therapy.
Your Title
This is the description area. You can write an introduction or add anything you want to tell your audience. This can help potential listeners better understand and become interested in your podcast. Think about what will motivate them to hit the play button. What is your podcast about? What makes it unique? This is your chance to introduce your podcast and grab their attention.